YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)

This is an open-label, dose-escalation and cohort expansion study to evaluate the safety and preliminary efficacy of YSCH-01 in subjects with pulmonary metastasis of advanced solid tumors and advanced non-small cell lung cancer by nebulized inhalation administration. This study is consisting of two phases: the dose escalation phase and the cohort expansion phase.

Trial Details

NCT ID

NCT07793500

Phase

EARLY_PHASE1

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

YSCH-01

Locations (sample)

Beijing, China|39.9075,116.39723

Key Eligibility Criteria

Subjects are able to understand and comply with protocol requirements, in the investigator's judgment.
Subjects are willing to sign the informed consent form (ICF) before any study procedures are initiated.
Male or female patients aged ≥18 years old and ≤75 years old.
Dose escalation phase: Subjects with histologically or cytologically confirmed advanced unresectable/relapsed metastatic non-small cell lung cancer…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →